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INTRODUCTION
Stress exposure is a significant factor for the development of major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). According to the National Comorbidity Study, approximately 60% of men and 51% of women have been exposed to one or more traumatic events during their lifetime. It is estimated that 7.8% of the overall population experiences PTSD at some point in their lives, with females (10.4%) experiencing the disorder at significantly higher rates than males (5.0%) [1] .
Traditionally, affective disorders have been treated from a symptom-suppression approach. Existing drugs aim to mitigate the impact of these chronic diseases, but do not cure or prevent the disease itself. However, if drugs were developed that enhance stress resilience, they could potentially be used in at-risk populations to protect against stress-induced psychiatric disorders.
We and others have recently reported that (R,S)-ketamine acts as a resilience enhancing drug (e.g., prophylactic) against stress when administered 1 week before stress in mice [2] [3] [4] [5] [6] . In addition, limited data in human patients have demonstrated (R,S)-ketamine's potential in preventing psychiatric disorders such as PTSD [7] and, potentially in a dose-specific manner, post-partum depression (PPD) [8, 9] . Prophylactic drug efficacy has been limited to (R,S)-ketamine until recently when Gould and colleagues reported that group II metabotropic glutamate receptor (mGlu2/3) antagonists are also protective [10] . We have previously reported that the SSRI Flx is ineffective as a prophylactic, but it remains to be determined if other serotonergic drugs could be effective prophylactics and/or if the serotonergic system is involved in prophylactic efficacy.
Numerous studies have implicated the 5-HT4Rs as a target for treating depression and anxiety. 5-HT4Rs are metabotropic G-protein coupled receptors that stimulate the Gs/cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling pathway in response to . 5-HT4Rs are highly expressed in the periphery, including the heart and adrenal gland, as well as in the brain in areas such as the amygdala, medial prefrontal cortex (mPFC), nucleus accumbens (NAc), and hippocampus (HPC) [15, 16] . 5-HT4R knockout mice display increased anxiety-like behavior and depressive-like behavior, while activation of 5-HT4Rs stimulates neurogenesis in the HPC and produces rapid-acting antidepressant-like effects [17] [18] [19] [20] .
However, if and how 5-HT4Rs are involved in stress resilience has yet to be determined.
Here, we hypothesized that since 5-HT4Rs have been heavily implicated in depression and anxiety, they may have a role in stress resilience. We focused our studies on three 5-HT4R agonists with varying affinity. First, RS-67,333 (1-(4-amino-5chloro-2-methoxyphenyl)-3-[1(n-butyl)-4-piperidinyl]-1-propanone HCl) is a high-affinity 5-HT4R partial agonist [21] . This drug is effective in improving behavioral deficits, decreasing the number of amyloid plaques as well as level of Ab species, and decreasing hippocampal astrogliosis and microgliosis in the 5XFAD mouse model of Alzheimer's disease (AD) [22] . Second, prucalopride (4-amino-5-chloro-2,3-dihydro-N-[1-3-methoxypropyl)-4-piperidinyl]-7-benzofuran carboxamide monohydrochloride) is a selective, high affinity 5-HT4R agonist [23] . In 2018, it was approved by the FDA for chronic constipation and is currently being tested for chronic intestinal pseudoobstruction. Prucalopride has also been tested in two separate clinical trials to investigate its effects on emotional processing in health volunteers after an acute (e.g. 6 single dose) or chronic (e.g. 1 week) administration [24, 25] . Third, PF-04995274 (4-[4-
tetrahydropyran-4-ol) is a potent, partial 5-HT4R agonist [26] . A clinical trial was conducted to evaluate PF-04995274, alone or in combination with donepezil, on scopolamine-induced deficits in psychomotor and cognitive function in healthy adults; however, this trial was terminated, but not due to safety concerns [27] . Currently, a clinical trial is underway to test whether adjunctive administration of PF-04995247 has positive effects on emotional processing and neural activity in mediated, treatmentresistant (TRD) depressed patients compared to placebo [28] .
To determine if 5-HT4R agonists may be potential prophylactics against stress, we utilized two different stress models (acute and chronic) in two different strains of mice (C57BL/6NTac and 129S6/SvEv). We found that RS-67,333, prucalopride, and PF-04995274 attenuate learned fear. Additionally, prucalopride, and PF-04995274 also decrease stress-induced depressive-like behavior in the FST. These effects were limited to male mice, as we did not determine prophylactic efficacy of RS-67,333 in female 129S6/SvEv mice. These data suggest that the 5-HT4R receptor may be a novel target for prophylactic development.
MATERIALS AND METHODS

Mice:
C57BL/6NTac mice: Male C57BL/6NTac mice were purchased from Taconic Farms (Lille Skensved, Denmark) at 8 weeks of age and were housed 5 per cage before the start of CORT treatment. All testing was conducted in compliance with the laboratory animal care guidelines and with protocols approved by the Institutional Animal Care and Use Committee (IACUC) (European Directive, 2010/63/EU for the protection of laboratory animals, permissions # 92-256B, authorization ethical committee CEEA n°26 2012_098). All mice were housed in a 12-h (06:00-18:00) light-dark colony room at 22°C. Food and water were provided ad libitum. Behavioral testing was performed during the light phase.
129S6/SvEv mice:
Male and female 129S6/SvEvTac mice were purchased from Taconic (Hudson, NY) at 7 weeks of age. The procedures described herein were conducted in accordance with the National Institutes of Health (NIH) regulations and approved by the IACUC of the New York State Psychiatric Institute (NYSPI). All mice were housed in a 12-h (06:00-18:00) light-dark colony room at 22°C. Food and water were provided ad libitum. Behavioral testing was performed during the light phase.
Drugs:
All drugs were prepared in physiological saline and all injections were administered intraperitoneally (i.p.) in volumes of 0.1 cc per 10 mg body weight unless otherwise noted.
Stress models:
Corticosterone (CORT) model: In this model, glucocorticoid levels are exogenously increased in C57BL/6NTac mice. This chronic CORT elevation dysregulates the hypothalamic-pituitary-adrenal axis (HPA) in a manner similar to that observed in clinical depression. For example, there is a blunting of the HPA-axis response to stress in CORT-treated mice, as shown by marked attenuation of stress-induced CORT levels [19, 29] . This model reliably induces anxious and depressive-like behavior in mice. The dose and duration of CORT treatment was selected based on previous studies [19, 29] .
CORT (35 µg/ml, equivalent to about 5 mg/kg/day) dissolved in 0.45 % hydroxypropyl-b-cyclodextrin (b-CD) or vehicle (VEH) (0.45% b-CD) was available ad libitum in the drinking water in opaque bottles to protect it from light. VEH-and CORTtreated water was changed every 3 days to prevent any possible degradation.
Contextual Fear Conditioning (CFC):
A 3-shock CFC procedure was administered as previously published [30, 31] . Briefly, mice were placed into context A and administered 3 2-s shocks (0.75 mA) at 180 s, 240 s or 300 s following placement into context A.
Mice were removed from the context 15 s following the termination of shock (at 317 s).
For context retrieval, mice were placed back into context A for 300 s.
Drugs:
Fluoxetine hydrochloride (Flx): Flx (BioTrend Chemicals AG, BG197) was administered in the drinking water (18 mg/kg/day) for 3 weeks before the start of CORT. For all experiments, unless otherwise noted, one-or two-way ANOVAs with repeatedmeasures were applied to the data as appropriate. Significant main effects and/or interactions were followed by Fisher's PLSD post hoc analysis or unpaired t-tests. All main effects, interactions, and p values are listed in Supplemental Table S01 .
RS
RESULTS
Chronic administration of RS-67,333 is prophylactic against stress in male mice
We have previously reported that chronic Flx administration (3 weeks of administration)
is not prophylactic against chronic CORT administration [3] . However, it remained to be determined if other serotonergic drugs could act as prophylactics. Here, we administered Flx (18 mg/kg/day) in the drinking water or RS-67,333 (1.5 mg/kg/day) in osmotic minipumps for 3 weeks prior to CORT administration in C57Bl/6NTac male mice followed by a series of behavioral assays, including the elevated plus maze (EPM), novelty-suppressed feeding (NSF), and sucrose splash test (ST) ( Fig. 1a-1b ).
CORT increased body weight over the 6-week behavioral protocol, as previously observed [32], ( Fig. 1c-1f total distance traveled in the EPM did not differ between any of the groups (Fig. 1i) . Next, the NSF task was administered to assay innate, anxiety-like behavior ( Fig.   1j-1k ). CORT + Veh mice exhibited an increased latency to approach the food pellet when compared with VEH + Veh mice. CORT + RS-67,333, but not CORT + Flx mice exhibited a significantly decreased latency to approach the pellet when compared with CORT + Veh mice.
Finally, in the ST, CORT + Veh mice exhibited decreased grooming duration when compared with VEH + Veh mice ( Fig. 1l) . CORT + RS-67,333, but not CORT + Flx mice exhibited increased grooming duration when compared with CORT + Veh mice. These data suggest that chronic RS-67,333, but not chronic Flx administration is prophylactic against CORT-induced behavioral abnormalities.
A single injection of RS-67,333 attenuates learned fear and protects against stressinduced hypophagia in male mice
Previously, we have shown that a single injection of (R,S)-ketamine is prophylactic against stress-induced depressive-like behavior and attenuates learned fear in 129S6/SvEv mice [3] . Here, we sought to determine if a single injection of RS-67,333 could also prevent a variety of maladaptive behaviors following a single, acute stressor.
Male 129S6/SvEv mice were injected with saline or RS-67,333 (1.5, 10, or 30 mg/kg) ( Fig. 2a) . One week later, mice were administered a 3-shock CFC paradigm. Mice administered 30, but not 1.5 or 10 mg/kg, of RS-67,333 exhibited significantly less freezing during CFC training when compared with mice administered saline ( Fig. 2b) .
Five days later, mice were re-exposed to the training context. Mice administered 1.5 or 10, but not 30 mg/kg of RS-67,333 exhibited significantly less freezing when compared with mice administered saline ( Fig. 2c-2d ).
Following CFC, mice were administered the FST. On Day 1, mice administered 10, but not 1.5 or 30 mg/kg, of RS-67,333 were significantly less immobile when compared with saline mice ( Fig. 2e) . However, on Day 2, immobility time was comparable between all groups ( Fig. 2f-2g ).
Next, mice administered saline or RS-67,333 (10 mg/kg) were tested in the OF.
Both groups of mice travelled a comparable distance ( Fig. 2h) and spent a comparable amount of time in the center of the arena (Fig. 2i) . Subsequently, mice were tested in the EPM, and neither in the open arms nor entries into the open arms of the maze was significantly different between saline or RS-67,333 mice ( Fig. 2j-2k ).
Finally, mice were administered the NSF. Mice given prophylactic RS-67,333 (10 mg/kg) exhibited a significantly reduced latency to approach the pellet ( Fig. 2l-2m ).
However, neither food eaten in the home cage nor weight loss following food deprivation differed between the groups (Fig. 2n-2o ). Together, these data indicate that a single injection of RS-67,333 is effective as a prophylactic in attenuating learned fear and preventing stress-induced hypophagia, but not depressive-like behavior, as measured by the FST, in male 129S6/SvEv mice.
A single prophylactic injection of RS-67,333 is not prophylactic against stress in female mice
We next sought to determine if a single injection of RS-67,333 could also be prophylactic in female mice. Female 129S6/SvEv mice were injected with saline or RS-67,333 (1.5 or 10 mg/kg) ( Fig. 3a) . One week later, mice were administered a 3-shock CFC paradigm. All groups of mice exhibited comparable levels of freezing during CFC training ( Fig. 3b) . Five days later, mice were re-exposed to the training context. Again, all groups of mice exhibited comparable levels of freezing ( Fig. 3c-3d ).
Following CFC, mice were administered the FST. During days 1 (Fig. 3e ) and 2 ( Fig. 3f-3g ) of the FST, all groups of mice had comparable levels of immobility. These data indicate that a single injection of RS-67,333 is not effective as a prophylactic in attenuating learned fear or in decreasing stress-induced depressive-like behavior in female 129S6/SvEv mice.
A single prophylactic injection of prucalopride or PF-04995274 is prophylactic against stress in male mice
We next sought to determine if other 5-HT4R agonists could also be prophylactic in male 129S6/SvEv mice. Male 129S6/SvEv mice were injected with saline, (R,S)ketamine (30 mg/kg), prucalopride (3 or 10 mg/kg), or PF-04995274 (3 or 10 mg/kg) ( Fig. 4a) . One week later, mice were administered a 3-shock CFC paradigm. All groups of mice exhibited comparable levels of freezing during CFC training ( Fig. 4b) . Five days later, mice were re-exposed to the training context. As we have previously published, (R,S)-ketamine attenuated learned fear ( Fig. 4c-4d ). Interestingly, prucalopride at 3, but not 10 mg/kg and PF04995274 at 10, but not 3 mg/kg, attenuated learned fear when compared with saline administration.
Following CFC, mice were administered the FST. During day 1, all groups of mice had comparable levels of immobility ( Fig. 4e) . During day 2, (R,S)-ketamine administration decreased immobility time when compared with saline administration ( Fig. 4f-4g ). Moreover, prucalopride at 3, but not 10 mg/kg and PF04995274 at 10, but not 3 mg/kg decreased immobility time when compared with saline administration. mice traveled a comparable distance (Fig. 4h) . In the EPM, all groups of mice spent comparable time in the open arms ( Fig. 4i) and entered into the open arms a comparable number of times (Fig. 4j) . In the NSF paradigm, all groups of mice approached the pellet in a comparable amount of time ( Fig. 4k-4l ). Finally, all mice lost a comparable amount of weight during the NSF paradigm, suggesting that prucalopride and PF04995274 do not impact weight loss (Fig. 4m) . In summary, these data indicate that a single injection of prucalopride or PF0499574, two 5-HT4R agonists, results in prophylactic efficacy by attenuating learned fear and decreasing stress-induced depressive-like behavior. However, these drugs are not prophylactic against stressinduced anxiety-like behavior.
DISCUSSION
Here, we hypothesized that novel 5-HT4R agonists could be prophylactic against fear, depressive-like, and/or anxiety-like behavior. We tested if three 5-HT4R agonists with varying affinity (e.g., partial or selective agonists) could protect against stress in two mouse strains by utilizing a chronic CORT administration or a CFC paradigm. Chronic administration of RS-67,333 was efficacious as a prophylactic against CORT stress. A single injection of RS-67,333 attenuated learned fear and prevented stress-induced hypophagia in the NSF in male, but not female 129S6/SvEv mice. RS-67,333 was ineffective against stress-induced depressive-like behavior, as measured by the FST, and anxiety-like behavior. A single injection of either prucalopride or PF-04995274 attenuated learned fear and decreased depressive-like behavior but had no effect on anxiety-like behavior. These data show that in addition to (R,S)-ketamine, 5-HT4R agonists are also effective prophylactics against stress, suggesting that the 5-HT4R receptor may be a novel target for prophylactic drug development.
The three 5-HT4R agonists chosen in this study have differential affinity to the 5-HT4R ( Fig. 5) . RS-67,333 and PF-04995274 are high affinity 5-HT4R partial agonists, whereas prucalopride is a selective, high affinity 5-HT4R agonist. RS-67,333 attenuated learned fear and protected against novelty-induced hypophagia, but did not decrease stress-induced depressive-like behavior. Prucalopride and PF-04995274 attenuated learned fear and decreased depressive-like behavior but had no effect on various measures of anxiety-like behavior. These data suggest that the unique combination of high pKi and partial selectivity for the 5-HT4R exhibited by RS-67,333 is sufficient to prevent against anxiety-like behavior whereas the differential activity of prucalopride and PF-04995274 at the 5-HT4R protect against stress-induced depressive-like behavior. Further study is necessary to determine if and how the 5-HT4R may contribute to the neurobiological mechanisms underlying stress resilience.
The expression and activity of 5-HT4Rs within the central nervous system (CNS) and periphery may provide insight into these mechanisms. In the brain, 5-HT4Rs are highly expressed in areas of the brain heavily involved in processing emotion, including the HPC, AMG, and PFC [11, 15, 20, 33, 34] . In addition to a multitude of other functions, such as modulating dopamine and acetylcholine release [34] as well as facilitating synaptic plasticity [34], 5-HT4Rs are known to interact with the calcium effector protein p11 [35] . More specifically, 5-HT4Rs are highly co-expressed with p11, which increases surface expression of the receptor in the HPC and AMG, facilitates its downstream signaling pathways, and is necessary for the antidepressant effects of 5-HT4R stimulation [35, 36] . Moreover, levels of p11 are significantly correlated with measures of suicidality and PTSD, indicating its potential as a biomarker for current suicidal ideation (CSI) and PTSD [37] [38] [39] . Additionally, 5-HT4R expression and activity in the PFC is regulated by casein kinase 2 (CK2), which may be an important modulator of depressive-and anxiety-like behaviors [40] . Further studies examining 5-HT4R agonists and their effects on these cellular regulators of 5-HT4R expression and activity could yield further insight into the protective properties of RS-67,333, prucalopride, and PF-
04995274.
In addition to the actions of 5-HT4R agonists within the brain, it is likely that these compounds exert additional changes within the periphery. 5-HT4Rs are expressed in a wide variety of peripheral areas of the body, such as the enteric nervous system (ENS), adrenal glands, and heart [16] . Importantly, 5-HT4Rs play a major role in maintaining communication along the gut-brain axis. Recent data indicate that microbiota in the ENS communicate with the central nervous system (CNS) by stimulating 5-HT4Rs present throughout the gut to stimulate serotonin release in the brain [41] . Concurrently, numerous previous studies have shown that activation of 5-HT4Rs is neuroprotective against oxidative stress, reduces inflammation, and stimulates neurogenesis in the brain and ENS [41] [42] [43] . Our manipulations may have stimulated gut-brain communication to promote neuroprotection and neurogenesis and thereby, enhance resilience against stress-induced fear, depressive-like, and/or anxiety-like behavior. We hypothesize that this action may have had an additive effect on the numerous, well-characterized consequences of 5-HT4R stimulation in the brain, such as increasing neuronal firing in the medial PFC (mPFC) and enhancing mitogenesis in the HPC [18, 33] , although this remains to be determined in future studies.
To develop safe and efficacious pharmacological methods of enhancing stress resilience it will be necessary to determine the toxicity of 5-HT4R agonists. Because 5-HT4Rs are so widely expressed throughout the periphery, chronic exposure to these drugs could result in negative outcomes [16] . We found that repeated dosing of RS-67,333 did not result in adverse side effects. However, because we did not conduct additional assays, such as assessing changes in cardiovascular activity or liver toxicity, it is impossible to know if repeated 5-HT4R agonist exposure would be harmful to peripheral organs. Nonetheless, the drugs that we tested were efficacious in enhancing stress resilience even after a single dose, indicating that 5-HT4Rs may be a critical target for developing prophylactic compounds. Further study will be necessary to determine whether single-dose 5-HT4R agonists can be developed to prevent stressinduced anxiety-like behavior.
Utilization of numerous mouse strains is essential in determining drug efficacy.
While C57BL/6 mice are the most widely used inbred strain, these mice may not be optimized to model susceptibility to stress. Numerous previous reports have shown opposing conclusions if mice of varying genetic backgrounds are tested in the same biological and behavioral assays [44] . These studies suggest that phenotypic relationships cannot be inferred by studying a single genetic background. Here, we utilized two strains -C57BL/6NTac (e.g., resilient) and 129S6/SvEv (e.g., susceptible) mice -in order to validate our effects of RS,67-333 in both a neuroendocrine model of stress and a fear-based stressor. In the C57BL/6NTac mice, we found prophylactic RS-67,333 was effective at decreasing depressive-and anxiety-like behavior, whereas in the 129S6/SvEv mice, we found prophylactic RS-67,333 was effective at attenuating learned fear, but not decreasing depressive-like behavior. Moving forward, numerous strains should be utilized in stress studies in order to infer drug-behavioral relationships.
Despite numerous studies showing prophylactic efficacy in male rodents, only one study to date has shown prophylactic efficacy in female rodents [45] . Maier and colleagues showed that (R,S)-ketamine administered 1 week prior to an uncontrollable stressor reduced stress-induced activation of the dorsal raphe nucleus (DRN) and eliminated DRN-dependent juvenile social exploration deficits in female rats. However, this study did not measure fear, depressive-like, and anxiety-like behavior in the rodents as done here. Nonetheless, we show that RS-67,333 is an ineffective prophylactic in female 129S6/SvEv mice at the varying doses administered. Prophylactic efficacy of has shown that female C57BL/6NTac mice are insensitive to chronic CORT [46] . Future studies are necessary to determine the sex-and dose-specific effects of prophylactic compounds, as twice as many women as men have a lifetime diagnosis of MDD [47] .
Overall, the present study has identified three novel compounds to be effective prophylactics against two types of stress. While prophylactics were not effective in female mice, they were in male mice, in accordance with previous (R,S)-ketamine studies. These data suggest that the 5-HT4R may be a novel target for prophylactic development and future studies may lead to novel insights on how 5-HT4R agonists administered prior to a stressor result in stress resiliency.
FUNDING AND DISCLOSURE
BKC, IM-D, CF, DJD, AMG, and CAD are named on provisional patent applications for the prophylactic use of (R,S)-ketamine and other compounds against stress-related psychiatric disorders. 
